Aug 2015 $61 M No. 7 $50 to $250 million 19
Syndax Pharmaceuticals Inc: Raise no. 7, Aug 2015 × Investors in this round 19 investors had bought by the notice of Aug 28, 2015: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $61 M of $61 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Briggs W Morrison, M.D. · Executive Officer, Director John Pallies · Executive Officer Michael W Metzger · Executive Officer Dennis Podlesak · Director Fabrice Egros, Ph.D. · Director George W Sledge, Jr., M.D. · Director Henry W Chen · Director Ivor Royston, M.D. · Director Kim Kamdar, Ph.D · Director Luke Evnin, Ph.D. · Director Richard P Shea · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John Pallies, Chief Financial Officer. Newest notice filed Aug 28, 2015. Read the notice at the SEC .
equity SEC Jun 2015 $24 M No. 6 $10 to $50 million 12
Syndax Pharmaceuticals Inc: Raise no. 6, Jun 2015 × Investors in this round 12 investors had bought by the notice of Jun 15, 2015: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $24 M of $45 M offered; $21 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Pallies · Executive Officer Michael W Metzger · Executive Officer Dennis Podlesak · Director Fabrice Egros, Ph.D. · Director George W Sledge, Jr. M.D. · Director Henry W Chen · Director Ivor Royston · Director Kim Kamdar, Ph.D · Director Luke Evnin, Ph.D. · Director Richard P Shea · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John Pallies, Chief Financial Officer. Newest notice filed Jun 15, 2015. Read the notice at the SEC .
equity SEC Feb 2014 $2 M No. 5 Under $2 million 3
Syndax Pharmaceuticals Inc: Raise no. 5, Feb 2014 × Investors in this round 3 investors had bought by the notice of Feb 13, 2014: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Arlene Morris · Executive Officer, Director John Pallies · Executive Officer Dennis Podlesak · Director Fabrice Egros, Ph.D. · Director George W Sledge, Jr. M.D. · Director Ivor Royston · Director Kim Kamdar, Ph.D · Director Luke Evnin, Ph.D. · Director Richard P Shea · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Arlene Morris, Chief Executive Officer. Newest notice filed Feb 13, 2014. Read the notice at the SEC .
options SEC Jan 2014 $1 M No. 4 Under $2 million 4
Syndax Pharmaceuticals Inc: Raise no. 4, Jan 2014 × Investors in this round 4 investors had bought by the notice of Feb 13, 2014: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Arlene Morris · Executive Officer, Director John Pallies · Executive Officer Dennis Podlesak · Director Fabrice Egros, Ph.D. · Director Ivor Royston · Director Kim Kamdar, Ph.D · Director Luke Evnin, Ph.D. · Director Richard P Shea · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Arlene Morris, Chief Executive Officer. Newest notice filed Feb 13, 2014. Read the notice at the SEC .
options SEC Mar 2013 $31 M No. 3 $10 to $50 million 18
Syndax Pharmaceuticals Inc: Raise no. 3, Mar 2013 × Investors in this round 18 investors had bought by the notice of Aug 30, 2013: 18 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $31 M of $48 M offered; $17 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Arlene Morris · Executive Officer, Director · Chief Executive Officer and Director Dennis Podlesak · Director Fabrice Egros · Director Kim Kamdar, Ph.D. · Director Luke Evnin, Ph.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Arlene Morris, Chief Executive Officer. Newest notice filed Aug 30, 2013. Read the notice at the SEC .
equity SEC Aug 2010 $6 M No. 2 $2 to $10 million 12
Syndax Pharmaceuticals Inc: Raise no. 2, Aug 2010 × Investors in this round 12 investors had bought by the notice of Aug 5, 2010: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $7 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Joanna Horobin, M.D. · Director, Executive Officer · President and Chief Executive Officer Robert Goodenow, PhD · Executive Officer Dennis Podlesak · Director Kim Kamdar, PhD · Director Rosina Maar Pavia, M.D. · Director Steven St. Peter, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Joanna Horobin, M.D., President and Chief Executive Officer. Newest notice filed Aug 5, 2010. Read the notice at the SEC .
debt, options SEC Jan 2010 $9 M No. 1 $2 to $10 million 13
Syndax Pharmaceuticals Inc: Raise no. 1, Jan 2010 × Investors in this round 13 investors had bought by the notice of Feb 3, 2010: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $16 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Joanna Horobin, M.D. · Director, Executive Officer · President and Chief Executive Officer Robert Goodenow, Ph.D. · Executive Officer Dennis Podlesak · Director Kim Kamdar, Ph.D. · Director Rosina Maar Pavia, M.D. · Director Steven St. Peter, M.D. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Joanna Horobin, M.D., President and Chief Executive Officer. Newest notice filed Feb 3, 2010. Read the notice at the SEC .
equity, options SEC